Swiss drugmaker Roche Holding AG announced Monday a $43.7 billion offer for the outstanding shares in biotech company Genentech Inc., to assist its hunt for new medicines.

Roche, based in Basel, Switzerland, plans to offer $89 per share for the 44 percent of Genentech that it doesn’t already own — or 8.8 percent more than the Friday closing price.